Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Biochem Pharmacol. 2019 Jan 30;163:21–31. doi: 10.1016/j.bcp.2019.01.022

Figure 7. CP-532,903 does not protect hearts from Adora3LoxP/LoxP;Myh6-Cre mice in which Adora3 is deleted specifically in cardiomyocytes form ischemia/reperfusion injury.

Figure 7.

Effect of CP-532,903 on recovery of left ventricular developed pressure (expressed as a percentage of baseline) of isolated hearts from Adora3LoxP/LoxP (Panel A) and Adora3LoxP/LoxP;Myh6-Cre (Panel B) mice subjected to 20 min of global ischemia and 45 min of reperfusion. Hearts were treated with either CP-532,903 (100 nM) or equivalent vehicle for 10 min prior to induction of ischemia. Insets show final recovery of left ventricular maximal ±dP/dt and coronary flow rate data at the end of the 45-min reperfusion period. Values shown are means ± SEM. *P<0.05 vs. vehicle-treated group. n = 10–13.